1. Home
  2. Regular

Dr Elizabeth Mallam - Neurology

Regular Off On A-Z of Consultants

GMC Number: 6071287

Year of first qualification: 2003, University of Edinburgh

Specialty: Neurology

Clinical interests: Functional neurological disorders, cognitive neurology

Secretary: Jennifer Littler (Functional Neurological Disorders)

Telephone: 0117 414 0451

Secretary: Ali Akber

Telephone: 0117 414 0352

Dr Mallam was an undergraduate at Cambridge and Edinburgh and has a PhD from Bristol University.  She completed her training in Edinburgh, London and Bristol. 

Dr Mallam joined North Bristol NHS Trust as a consultant neurologist in September 2017.  Her interests are in functional neurological disorders and cognitive neurology.

Related links

Mallam

Meeting Posters (ECCMID)

Regular Off Off

27th ECCMID Vienna April 2017

Reference No.

Document title

 

The antibacterial effect (ABE) of ceftolozane (TOL)/tazobactam (TAZ) plus amikacin (AMI) against Pseudomonas aeruginosa (PA) using simulated human dosing

 

 

Results of a Prospective Randomised Multicentre Trial to assess the Impact of Laboratory Based Rapid Diagnostics using MALDI-TOF Technology on Outcomes of Patients with Blood Stream Infection (BSI) (RAPIDO Study)

 

 

26th ECCMID Amsterdam April 2016

Reference No.

Document title

P1257

Pharmacodynamics of Amikacin Inhale studied in an in vitro pharmacokinetic model of infection

 

 

Bad bugs, no drugs and no ESKAPE

 

P1127

Screening neonates for Pseudomonas aeruginosa; does it help prevent infection in babies at risk?

 

 

25th ECCMID Copenhagen April 2015

Reference No.

Document title

EVO268

Epidemiology of Antibiotic Resistance of E.coli, S.aureus and P.aeruginosa Isolated From Bloodstream Infections (BSI) Across 5 Centres in England and Wales During 2010-2012

 

 

23rd ECCMID Berlin April 2013

Reference No.

Document title

P1582

MIC distributions of MRSA to ceftaroline, vancomycin, teicoplanin and daptomycin: potential problems for routine susceptibility testing

 

 

22nd ECCMID London March 2012

Reference No.

Document title

P1821

Bactericidal Activity of Fosfomycin against NDM-1 producing Enterobacteriaceae

 

P676

Antimicrobial susceptibility testing of Listeria monocytogenes with EUCAST breakpoints: A multi‐laboratory study

 

P1624

Therapeutic drug monitoring of Daptomycin: a 4 year audit of levels from a UK clinical antibiotic service

 

 

21st ECCMID Milan May 2011

Reference No.

Document title

P795Antibacterial effect of ceftaroline against MRSA and VISA strains studied in an in vitro pharmacokinetic model of infection

P729Impact of inoculum on the antibacterial effect of levofloxacin and moxifloxacin against S. pneumoniae strains with defined resistance mechanisms studied in an in vitro model of infection

 

Bcare (ARL) Contact Details

Antimicrobial Reference Laboratory
Level 2, Phase 1, Pathology Sciences Building
Southmead Hospital
Westbury-on-Trym
Bristol
BS10 5NB

Telephone: 0117 4146269 or 0117 4146220

Fax: 0117 4146282

Email: arlenquiries@nbt.nhs.uk

Meeting Posters (ICAAC)

Regular Off Off

55th ICAAC, San Diego, September 2015

Reference No.

Document title

Authors

A-471

Pharmacodynamics of aztreonam against E.coli studied in an in vitro model of infection

 

C Ramsey, KE Bowker, AR Noel, MLG Attwood, ST Tomaselli, A P MacGowanA-472

Pharmacodynamics of Ceftaroline Against Proteus mirabilis
Pre-clinical Clinical Correlates

 

A. Noel, K. Bowker, S. Tomaselli, M. Attwood, A. MacGowanA-497

Pharmacodynamics of minocycline plus rifampicin against S.aureus studied in an in vitro model of infection

 

KE Bowker, AR Noel, MLG Attwood, ST Tomaselli, AP MacGowanA-506

Comparison of the Antibacterial Effects of Two Dosing Regimens of Ceftolozane (TOL) in Combination with Tazobactam (TAZ) against Enterobacteriaceae

 

KE Bowker, AR Noel, MLG Attwood, ST Tomaselli, AP MacGowan

 

54th ICAAC, Washington DC, September 2014

Reference No.

Document title

Authors

A-040

Pharmacodynamics of Minocycline against Acinteobacter baumannii studied in a pharmacokinetic Model of Infection

 

KE Bowker, AR Noel, SG Tomaselli, D Nicholls, AP MacGowanA-042

Pharmacodynamics of Amikacin against Aerobic Gram-negative Rods studied in an in vitro Model of Infection

 

AR Noel, KE Bowker, SG Tomaselli, D Nicholls, AP MacGowanA-1347

Pharmacokinetic driver of avibactam effect against β-lactamase-producing Enterobacteriaceae established in an in vitro pharmacokinetic model of infection-1347

 

KE Bowker, AR Noel, SG Tomaselli, D Nicholls, AP MacGowan

A-1182Pharmacodynamics of ceftolozane/tazobactam against P.aeruginosa (PSA) Studied in an In Vitro Model of Infection.KE Bowker, AR Noel, SG Tomaselli, D Nicholls, AP MacGowan

A-1347a

Pharmacokinetic driver of avibactam effect against β-lactamase-producing Enterobacteriaceae
established in an in vitro pharmacokinetic model of infection

 

AP MacGowan, AR Noel, SG Tomaselli, D Nicholls, KE Bowker

 

53rd ICAAC, Denver, September 2013

Reference No.

Document title

Authors

A-1015

Pharmacodynamics of minocycline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection

 

AR Noel, KE Bowker, SG Tomaselli, , AP MacGowan, WW HopeA-1029

Pharmacodynamics of ceftolozane/tazobactam against Gram-negative bacilli

 

KE Bowker, AR Noel, SG Tomaselli, HG Elliott, AP MacGowanA-022

Pharmacodynamics of Glycopeptides in Combination with Rifampicin for Methicillin Resistant Staphylococcus aureus (MRSA) Infections

 

J . Sharp , J. Livermore, L. Gregson, J. Goodwin, A.P. MacGowan, W.W. HopeA-464

fT>MIC Targets May Vary for Cephalosporins Within the Enterobacteriaceae Group

 

Karen E Bowker, Alan R Noel,1 Jane Ambler, Alasdair P MacGowanA-009

Pharmacodynamics of single dose Oritavancin against Staphylococcus aureus

 

KE Bowker, AR Noel, SG Tomaselli, HG Elliott, AP MacGowan

 

52nd ICAAC, San Francisco, September 2012

Reference No.

Document title

Authors

A-024

Pharmacodynamics of doripenem against Pseudomonas aeruginosa and Acinetobacter spp

 

AR Noel, KE Bowker, SG Tomaselli, AP MacGowanA-628

Assessment of the Antistaphylococcal Effect of Ceftaroline in
Long Duration Human Dose Simulations: Impact of MIC

 

AR Noel, KE Bowker, SG Tomaselli, AP MacGowanA-629

Pharmacodynamics of Ceftaroline against Enterobacteriaceae

 

AR Noel, KE Bowker, SG Tomaselli, AP MacGowanA-631

The pharmacodynamics of Avibactam (NXL104) in Cobination with Either Ceftaroline or Ceftazidime against Blactamase producing Enterobacteriaceae

 

AR Noel, SG Tomaselli, DL Nicholls, KE Bowker, G Williams, AP MacGowanA-642

Pharmacodynamics of piperacillin-tazobactam (P/T) against Pseudomonas aeruginosa: antibacterial effect and risk of emergence of resistance

 

AR Noel, KE Bowker, AP MacGowanD-763

Colistin MIC Testing: The Effect of Different Types of Microtitre Trays and Surfactant Tween 80 in Broth Microdilution Method

 

E Sweeney, S Nelson, A Lovering, K BowkerE-793

Bactericidal Activity of Multiple Combinations of Fosfomycin and Colistin against NDM-1 producing Enterobacteriaceae

 

KE Bowker, AP MacGowan

 

51st ICAAC, Chicago, Sep 2011

Reference No.

Document title

Authors

A2-556

Pharmacodynamics of Avibactam Plus Either Ceftaroline or Ceftazidime Against an AmpC-Producing Enterobacter spp

 

AR Noel, KE Bowker, AP MacGowan, G WilliamsA2-557

Pharmacodynamics of Ceftaroline Plus Avibactam Against Enterobacteriaceae Studied in an In Vitro Pharmacokinetic Model of Infection

 

K.E. Bowker, A.R. Noel, S.G. Tomaselli, A.P. MacGowan, G. WilliamsA1-1159/6

Pharmacokinetics and Safety of Daptomycin in Young Infants

 

P Brian Smith, Michael Cohen-Wolkowiez, Kevin Watt, Daniel K Benjamin Jr.E-721

Bactericidal Activity of Multiple Combinations of Tigecycline and Colistin against NDM-1 producing Enterobacteriaceae

 

M. Albur, A. Noel, K. Bowker, A. MacGowanA2-555

Pharmacodynamics of Ceftaroline against Staphylococcus aureus
Studied in an In Vitro Pharmacokinetic Infection Model

 

Alan R Noel, Karen E Bowker, Sharon G Tomaselli, Alasdair P MacGowanC2-093

Community-based Nasal Screening Poorly Predicts pvl Carriage and Antimicrobial Resistance in Communityacquired
S.aureus Infection

 

A. Lovering, J. Sunderland, E. Woodward, J Steer, A. Hidalgo-ArroyoF1-314

A monobactam plus double b-lactamase inhibitor combination (BAL30376) designed to overcome multiple resistance in Gram-negative bacilli: proof of concept in an in vitro pharmacokinetic model

 

KE Bowker, AR Noel, AP MacGowan

 

50th ICAAC, Boston, Sep 2010

Reference No.

Document title

Authors

A1-673

Changes in Streptococcus pneumoniae population profiles after
exposure to fluoroquinolones in prolonged dosing simulations

 

KE.Bowker, AR.Noel, HC.Elliott, SG.Tomaselli and AP.MacGowanA1-1383

Pharmacodynamics of Razupenem (PTZ601) against Enterobacteriaceae

 

KE. Bowker, AR. Noel, SG. Tomaselli, HC. Elliott, AP. MacGowanA1-1367

The magnitude of the pharmacodynamic index required for a 24h bacteriostatic effect for S.aureus is associated with increased risk of resistance

 

KE. Bowker, AR. Noel, HC. Elliott, SG. Tomaselli and AP. MacGowanA1-1377

Comparison of the Antibacterial Effects of Two Dosing Regimens of Ceftaroline in Combination With NXL104 Against Enterobacteriaceae

 

K. Bowker, A. Noel, H. Elliott, S. Tomaselli, A. MacGowanA1-1382

Pharmacokinetic-Pharmacodynamic Basis for CLSI Carbapenem Susceptibility Breakpoint Changes

 

Sujata M. Bhavnani, Michael N. Dudley, Cornelia Landersdorfer, George L. Drusano, William A. Craig, Ronald N. Jones, Paul G. Ambrose

 

Bcare (ARL) Contact Details

Antimicrobial Reference Laboratory
Level 2, Phase 1, Pathology Sciences Building
Southmead Hospital
Westbury-on-Trym
Bristol
BS10 5NB

Telephone: 0117 4146269 or 0117 4146220

Fax: 0117 4146282

Email: arlenquiries@nbt.nhs.uk

PK/PD articles

Regular Off Off

pK papers

Title

Authors
Bone penetration of intravenous flucloxacillin and gentamicin as antibiotic prophylaxis during total hip and knee arthroplasty. Torkington MS, Davison MJ, Wheelwright EF, Jenkins PJ, Anthony I, Lovering AM, Blyth M, Jones B. Bone Joint J. 2017 Mar;99-B(3):358-364
Therapeutic drug monitoring in the past 40 years of the Journal of Antimicrobial Chemotherapy. Reeves D, Lovering A, Thomson A. J Antimicrob Chemother. 2016 Dec;71(12):3330-3332
Amikacin use and therapeutic durg monitoring in adults: do dose regimens and drug exposures affect ither outcome or advers events? A systematic review Jenkins, A, Thomson AH, Brown NM, Semple Y, Sluman C, Macgowan A, Lovering AM, Wiffen PJ; (BSAC Working Party on Therapeutic Drug Monitoring)
J Antimicrob Chemother. 2016 Jul 11
A review of the pharmacokinetics and pharmacodynamics of aztreonam Ramsey C, MacGowan AP
J Antimicrob Chemother. 2016 June 21
Differences in the pharmacodynamics of ceftaroline against different species of Enterobacteriaceae studied in an in vitro pharmacokinetic model of infection Bowker KE, Noel AR, Tomaselli S, MacGowan AP
J Antimicrob Chemother. 2016 May;71(5):1270-8
The three wise monkeys of therapeutic drug monitoring. AM Lovering, T Elston. www.rcpath.org.uk April 2016 Issue 174
The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriacese in in vitro pharmacokenetic/pharmacodynamic model experiments Albur MS, Noel A, Bowker K, MacGowan A.
Int J Antimicrob Agents. 2015 Nov;46(5):560-7
Pharmacodynamics of Ceftolozane plus Tazobactam studied in an in vitro Pharmacokinetic model of infection MacGowan AP, Noel AR, Tomaselli SG, Nicholls D, Bowker KE
Antimicrob Agents Chemother. 2015 Nov 9;60(1):515-21
Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia Mpenge MA, MacGowan AP
Ther Clin Risk Manag. 2015 Apr 7;11:565-79
Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection MacGown AP, Noel AR, Tomaselli S, Bowker KE
Antimicrob Agents Chemother. 2013 Jun;57(6):2451-6
Comparative antibacterial effects of moxifloxacin and levofloxacin on Streptococcus pneumoniae strains with defined mechanisms of resistance: impact of bacterial inoculum Bowker KE, Garvey MI, Noel AR, Tomaselli SG, Macgowan AP
J Antimicrob Chemother. 2013 May;68(5):1130-8
Pharmacodynamics of the antibacterial effect of and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an in vitro pharmacokinetic model Bowker KE, Noel AR, Tomaselli SG, Elliott H, Macgowan AP
Antimicrob Agents Chemother. 2012 Oct;56(10):5009-15
Bactericidal activity of multiple combinations of tigecycline and colistin against NDM-1-producing Enterobacteriacese Albur M, Moel A, Bowker K, MacGowan A
Antimicrob Agents Chemother. 2012 Jun;56(6):3441-3
The role of pharmacokinetics/pharmacodynamics in setting clincial MIC breakpionts: the EUCAST approach Mouton JW, Brown DF, Apfalter P, Canton R, Giske CG, Ivanova M, Macgowan AP, Rodloff A, Soussy CJ, Steinbakk M, Kahlmeter G
Clin Microbiol Infect. 2012 Mar;18(3):E37-45
Role of early intravenos to oral antibiotic switch therapy in the management of prosthetic hip infection treated with one- or two- stage relacement Darley ES, Bannister GC, Blom AW, MacGowan AP, Jacobsen SK, Alfouzan W
J Antimicrob Chemother 2011 Oct;66(10):2405-8
Pharmacodynamics of razupenem (PZ601) studied in an in vitro pharmacokinetic model of infection MacGown AP, Noel A, Tomaselli S, Elliott H,
Bowker K.
Antimicrob Agents Chemother. 2011 Apr;55(4):1436-42
Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection MAcGowan AP, Noel A, Tomaselli S, Elliott H, Bowker KE.
Antimicrob Agents Chemother. 2011 Feb;55(2):867-73
Analyses of teicoplanin concentrations from 1994 to 2006 from a UK assay service Tobin CM, Lovering AM, Sweeney E, MacGowan AP
J Antimicrob Chemother 2010 Oct;65(10):2155-7
Pharmacokinetic evaluation of linezolid in patients with major thermal injuries Le Floch R, Amould JF, Vinsonneau C, Hovsepian L, Stephanazzi J, Bret P, Birraux G, Lovering AM
Pathol Biol (Paris) 2010 Apr;58(2):e27-31
Daptomycin in synovial fluid during treatment of methicillin-resistant Staphylococcus aureus septic arthritis Ritchie ND, Lovering AM, Seaton RA
J Antimicrob Chemother 2010 Jun;65(6): 1314-5
Potentially dangerous misuse of the Hartford once-daily nomogram for gentamicin Lovering AM, Reeves DS
J Antimicrob Chemother 2009 Nov;64(5): 1117-8
Concentration and bioavailability of ciprofloxacin and teicoplanin in the cornea Kaye SB, Neal T, Nicholson S, Szkurlat J, Bamber S, Baddon AC, Anderson S, Seddon K, Dwyer N, Lovering AM, Smith G
Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3176-84
Pharmacokinetic evaluation of linezolid in patients with major thermal injuries Lovering AM, Le Floch R, Hovsepian L, Stephanazzi J, Bret P, Birraux G, Vinsonneau CJ
Antimicrob Chemother 2009 Mar;63(3):553-9
Potentially dangerous use of the Hartford nomogram Lovering AM, Reeves DS
J Antimicrob Chemother 2009 Nov;64(5):1117-8
Pharmacokinetic evaluation of patients with major thermal injuries Le Floch R, Arnould JF, Vinsonneau C, Hovsepian L, Stephanazzi J, Bret P, Birraux G, Lovering AM
Pathol Biol (Paris) 2009 Oct 23 & J Antimicrob Chemother 2009 Mar;63(3):553-9
Concentration and bioavailability of ciprofloxacin and teicoplanin in the cornea Lovering AM, Le Floch R, Hovsepian L, Stephanazzi J, Bret P, Birraux G, Vinsonneau C
Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3176-84
The effect of a modified posterior approach on blood flow to the femoral head during hip resurfacing Khan A, Lovering AM, Bannister GC, Spencer RF, Kalap N
Hip Int 2009 19, 52-7
Concentration and bioavailability of ciprofloxacin and teicoplanin in the cornea Kaye SB, Neal T, Nicholson S, Szkurlat J, Bamber S, Baddon AC, Anderson S, Seddon K, Dwyer N, Lovering AM, Smith G
Invest Ophthalmol Vis Sci 2009 Jul;50(7):3176-84. Epub 2009 Feb 14
Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations Thomson AH, Staatz CE, Tobin CM, Gall M, Lovering AM
J Antimicrob Chemother 2009 May;63(5):1050-7
Measurements of in vivo intra-articular gentamicin levels from antibiotic loaded articulating spacers in revision total knee replacement Mutimer J, Gillespie G, Lovering AM, Porteous AJ
Knee 2009 Jan;16(1):39-41
An HPLC assay for daptomycin in serum Tobin CM, Darville JM, Lovering AM, Macgowan AP
J Antimicrob Chemother 2008 Dec;62(6):1462-3
Development, evaluation and application of an isocratic high-performance liquid chromatography (HPLC) assay for the simultaneous determination of aciclovir and its metabolite 9-carboxymethoxymethylguanine in human serum and cerebrospinal fluid Darville JM, Lovering AM, MacGowan AP
Int J Antimicrob Agents. 2007 Jul;30(1):30-3. Epub 2007 Apr 10
Evidence of excessive concentrations of 5-flucytosine in children aged below 12years: a 12 year review of serum concentrations from a UK clinical assay reference laboratory Soltani M, Tobin CM, Bowker KE, Sunderland, MacGowan AP, Lovering AM
Int J Antimicrob Agents 2006 Dec;28(6):574-7
Assay of ertapenem in human serum by High Performance Liquid Chromotgraphy Soltani M, MacGowan AP, Lovering AM
Int J Antimicrob Agents. 2006 Feb;27(2):165-7. Epub 2006 Jan 18
The pharmacokinetics of linezolid in the non-inflamed human eye JI Prydal, DR Jenkins, AM Lovering, A Watts
Br J Opthalmol. 2005 Nov; 89, 1418-9
Variability in the content of Indian generic ciprofloxacin eye drops Weir RE, Zaidi FH, Charteris DG, Bunce C, Soltani M, Lovering AM
Br J Ophthalmol. 2005 Sep;89(9):1094-6
Residual antibiotics in allograft heart valve tissue samples following antibiotic disinfection Leeming JP, Lovering AM, Hunt CJ
J Hosp Infect 2005 Jul;60(3):231-4
Pharmacokinetic studies of linezolid and teicoplanin in the critically ill T Whitehouse, JA Cepeda, R Shulman, L Aarons, R Nalda-Molina, C Tobin, AP MacGowan, S Shaw, C Kibbler, M Singer, AP Wilson
J Antimicrob Chemother 2005 Mar; 55, 333-40
Resistance determinants in strains of Clostridium difficile from two geographically distinct populations JS Bendle, PA James, PM Bennett, MB Avison, AP MacGowan, KM Al-Shafi
Int J Antimicrob Agents. 2004 Dec; 24, 619-21
Determination of Avilamycin A and B in pig faeces by solid phase extraction and reverse phase extraction Sunderland J, Lovering AM, Tobin CM, MacGowan AP, Roe JM, Delsol AA
Int J Antimicrob Agents 2004 Nov;24(5):511-4
Gentamicin concentrations in diagnostic aspirates from 25 patients with hip and knee arthroplasties Fletcher MD, Spencer RF, Langkamer VG, Lovering AM
Acta Orthop Scand. 2004 Apr;75(2):173-6
A reverse-phase HPLC assay for the simultaneous determination of enrofloxacin and ciprofloxacin in pig faeces Sunderland J, Lovering AM, Tobin CM, MacGowan AP, Roe JM, Delsol AA
Int J Antimicrob Agents. 2004 Apr;23(4):390-3
Topical vancomycin applied on closure of the sternotomy wound does not prevent high levels of systemic vancomycin J Desmond, AM Lovering, C Harle, T Djorevic, R Millner
Eur J Card Surg 2003 May;23, 765-70
Determination by HPLC of chlortetracycline in pig faeces Sunderland J, Lovering AM, Tobin CM, MacGowan AP, Roe JM, Delsol AA
J Antimicrob Chemother 2003 Apr; 51(4):1041-2
A high performance liquid chromatography assay for linezolid in continuous ambulatory peritoneal dialysis fluid CM Tobin, J Sunderland, AM Lovering, AP MacGowan
J Antimicrob Chemother. 2003 51, 1041-2
Variation in the disc content of ciprofloxacin susceptibility testing discs; its effect on the BSAC disc method Darville JM, Lovering AM
J Antimicrob Chemother. 2003 Feb; 51(2):465-7
Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement Lovering AM,Zhang J, Bannister GC, Lankaster BJ, Brown JH, Narendra G, MacGowan AP
J Antimicrob Chemother 2002 Jul; 50(1):73-7
Epidemiology and resource utilisation for patients hospitalized for lower reapiratory tract infection Lovering AM, MacGowan AP, Anderson P, Irwin D
Clin Microbiol Infect 2001 Dec;7(12):666-70
Pharmacokinetics of once-a-day netilmicin (4.5mg/kg) in neonates PE Gosden, KA Bedford, JJ Dixon, BD Speidel, AA Leaf, AP MacGowan
J Chemother. 2001 Sep; 13: 270-6
Difficullties in the assay of cefamandole highlight the importance of specific methodologies in pharmacokinetic studies Zhang J, Lovering AM
J Antimicrob Chemother. 2001 Jul;48(1):154-5
The penetration of ceftriaxone and cefamandole into bone, fat and haematoma and relevance of serum protein binding to their penetration into bone Lovering AM, Walsh TR, Bannister GC, MacGowan AP
J Antimicrob Chemother. 2001 Apr;47(4):483-6
Antimicrobial activity of fluoroquinolone photodegradation products determined by parallel-line bioassay and high performance liquid chromatography J Sunderland, CM Tobin, LO White, AP MacGowan, AJ Hedges
J Antimicrob Chemother 2001 Mar; 47: 271-6
Clinafloxacin serum concentrations in a patient on continuous veno-venous haemofiltration ES Darley, AP MacGowan, RA Howe, CM Tobin
J Antimicrob Chemother. 2000 Jun;45: 927-8
Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentration and outcome I Harding, AP MacGowan, LO White, ES Darley, V Reed
J Antimicrob Chemother 2000 Jun; 45: 835-42

 

pD papers

 

Title

Authors
Towards better antimicrobial susceptibility testing: impact of the Journal of Antimicrobial Chemotherapy. Wootton M, MacGowan AP, Howe RA. J Antimicrob Chemother. 2017 Feb;72(2):323-329.
The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection. MacGowan A, Tomaselli S, Noel A, Bowker K. J Antimicrob Chemother. 2017 Mar 1;72(3):762-769.
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1. Drusano GL, Louie A, MacGowan A, Hope W. Antimicrob Agents Chemother. 2015 Dec 28;60(3):1183-93.
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2. Drusano GL, Hope W, MacGowan A, Louie A. Antimicrob Agents Chemother. 2015 Dec 28;60(3):1194-201.
The role of pharmacokinetics/pharmacodynamics in setting clincalm breakpoints; the EUCAST approach. Mouton JW, Brown DF, Canton R, Apfaler P, Giske GC, Ivanova M, MacGowan AP, Rodloff AC, Soussy CJ, Steinbakk M, Kahlmeter G.
Clin Microbial Infection. 2011 Oct
EUCAST rules expert rules in antimicrobial susceptibility testing Leclercq R, Canton R, Brown DF, Giske GC, Heisig P, MacGowan AP, Mouton JW, Nordmann P, Rodloff AC, Soussy CJ, Steinbakk M, Winstanley TG, Kahlmeter GMacGowan A,
Clin Microbial Infection. 2011 Oct
Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective Mouton JW, Ambrose PG, Canton R, Drusano GL, Harbarth S, MacGowan A, Theuretzbacher U, Turnidge J
Drug Resist Updat. 2011 Apr;14(2):107-17
Pharmacodynamics of razupenem (PZ601) studied in an in vitro pharmacokinetic model of infection MacGowan AP, Noel A, Tomaselli S, Elliott H, Bowker K
Antimicrob Agents Chemother. 2011 Jan 24
The pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection MacGowan AP, Noel AR, Tomaselli S, Elliott HC, Bowker KE
Antimicrob Agents Chemother.2011 Feb;55(2):867-73
Use of intravenous co-trimoxazole to treat bacterial infection: analysis of 50 treatment episodes Barton E, MacGowan AP
J Chemother. 2010 Aug;22(4):267-9
Harmonization of antimicrobial susceptibility testing breakpoints in Europe: implications for reporting intermediate susceptibility Brown D, MacGowan A
J Antimicrob Chemother. 2010 Feb;65(2):183-5
Strain-to-strain variation on pharmacodynamic index a hitherto unconsidered factor in establishing antibiotic clinical breakpoints MacGowan AP, Reynolds R, Noel AR, Bowker KE
Antimicrob Agents Chemother. 2009 Dec;53(12):5181-4
Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an vitro model of infection Bowker KE, Noel AR, MacGowan AP
Antimicrob Agents Chemother. 2009 Nov; 64(5): 1044-51
Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model Bowker KE, Noel AR, MacGowan AP
Antimicrob Agents Chemother. 2008 Dec;52(12):4370-3
Tigecycline pharmacokinetic/pharmacodynamic update MacGowan AP
J Antimicrob Chemother 2008 Sep; 62 Suppl 1: 11-6
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an invitro pharmacokinetic model of Staphylococcus aureus infection MacGowan AP, Bowker KE, Noel AR
Antimicrob Agents Chemother. 2008 Apr;52(4):1401-6
Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide intermediate Staphylococcus aureus (GISA) and heterogenous (h)GISA isolates Wootton M, MacGowan AP, Walsh TR
Antimicrob Agents Chemother. 2006 Dec;50(12):4195-7
Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcylines Agwuh K, MacGowan AP
J Antimicrob Chemother. 2006 Dec, 58: 256-65
Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system Bowker KE, Noel AR, MacGowan AP
J Antimicrob Chemother 2006 Oct; 58(4):802-5
Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model Noel AR, Bowker KE, MacGowan AP
Antimicrob Agents Chemother. 2005 Oct;49 (10):4234-9
Pharmacodynamics of ceftazidime plus the serine beta-lactamase inhibitor AM-112 against Escherichia coli containing TEM-1 and CTX-M-1 beta lactamases Bowker KE, Noel AR, Walsh TR, Rogers CA, MacGowan AP
Antimicrob Agents Chemother 2004 Nov;48(11):4482-4
Antibacterial effects of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae strains for which MICs are high, in an in vitro pharmacokinetic model Bowker KE, Noel AR, Rogers CA, MacGowan AP
Antimicrob Agents Chemother. 2004 Jul;48(7):2599-603
In vitro studies on the impact of human serum on the antibacterial effect of faropenem AP MacGowan, K Bowker
J Chemother. 2004 Feb; 16, 23-9
Mechanism of fluoroquinolone resistance is an important factor in determining antimicrobial effect of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model MacGowan AP, Bowker KE
Antimicrob Agents Chemother. 2003 Mar;47(4):1096-100
Pharmacodynamics of linezolid in a clinical isolate of Streptococcus pneumoniae genetically modified to express lux genes HM Alloush, V Salisbury, RJ Lewis, AP MacGowan
J Antimicrob Chemother. 2003 Sep; 52, 511-3
Activities of moxifloxacin against, and emergence of resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model Bowker KE, Rogers CA, Holt HA, MacGowan AP
Antimicrob Agents Chemother. 2003 Mar;47(3):1088-95
The activity of vancomycin against heterogenous vancomycin-intermediate methicillin-resistant Staphylococcus aureus explored in an in vitro pharmacokinetic model Turner J, Howe RA, Wootton M, Bowker KE, Salisbury V, Bennett PM, Walsh TR, MacGowan AP
J Antimicrob Chemother 2001 Nov; 48(5):727-30
Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model MacGowan AP, Rogers CA, Wootton M, Holt HA, Bowker KE
Antimicrob Agents Chemother. 2001 Oct;45(10):2916-21

 

Bcare (ARL) Contact Details

Antimicrobial Reference Laboratory
Level 2, Phase 1, Pathology Sciences Building
Southmead Hospital
Westbury-on-Trym
Bristol
BS10 5NB

Telephone: 0117 4146269 or 0117 4146220

Fax: 0117 4146282

Email: arlenquiries@nbt.nhs.uk

PK/PD articles

Bcare Publications

Regular Off Off

BCARE regularly publishes data in peer reviewed journals and presents data at ICAAC and ECCMID conferences. please click on link to view pdfs where available.

Bcare (ARL) Contact Details

Antimicrobial Reference Laboratory
Level 2, Phase 1, Pathology Sciences Building
Southmead Hospital
Westbury-on-Trym
Bristol
BS10 5NB

Telephone: 0117 4146269 or 0117 4146220

Fax: 0117 4146282

Email: arlenquiries@nbt.nhs.uk

Bcare Publications

Bcare Research Articles

Regular Off Off

Title

Authors
In-vitro discrimination of wound associated bacteria by volatile compound profiling using Selected Ion Flow Tube - Mass Spectrometry. Slade EA, Thorn RMS, Lovering AM, Young A, Reynolds DM. J Appl Microbiol. 2017 Apr 19.
Antimicrobial resistance surveillance in urinary tract infections in primary care Chin TL, McNulty C, Beck C, MacGowan A
J Antimicrob Chemother. 2016 Jun 26
Early warning score: a dynamic marker of severity and prognosis in patients with Gram-negative bacteraemia and sepsis Albur M, Hamilton F, MacGowan AP
Ann Clin Microbiol Antimicrob. 2016 Apr 12;15:23
One-stage or two-stage revision surgery for prosthetic hip joint infection--the INFORM trial: a study protocol for a randomised controlled trial. Strange S, Whitehouse MR, Beswick AD, Board T, Burston A, Burston B, Carroll FE, Dieppe P, Garfield K, Gooberman-Hill R, Jones S, Kunutsor S, Lane A, Lenguerrand E, MacGowan A, Moore A, Noble S, Simon J, Stockley I, Taylor AH, Toms A, Webb J, Whittaker JP, Wilson M, Wylde V, Blom AW. Trials. 2016 Feb 17;17:90.
The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance. Kostyanev T, Bonten MJ, O'Brien S, Steel H, Ross S, François B, Tacconelli E, Winterhalter M, Stavenger RA, Karlén A, Harbarth S, Hackett J, Jafri HS, Vuong C, MacGowan A, Witschi A, Angyalosi G, Elborn JS, deWinter R, Goossens H. J Antimicrob Chemother. 2016 Feb;71(2):290-5.
Development and internal validation of a clinical rule to improve antibiotic use in children presenting to primary care with acute respiratory tract infection and cough: a prognostic cohort study. Hay AD, Redmond NM, Turnbull S, Christensen H, Thornton H, Little P, Thompson M, Delaney B, Lovering AM, Muir P, Leeming JP, Vipond B, Stuart B, Peters TJ, Blair PS, 2016 Lancet Respir Med 4:902-10
Management of the exposed total knee prosthesis, a six-year review K Young, S Chummun, T Wright, E Darley, T Chapman, A Porteous, J Murray, U Khan.  The Knee  23 (2016) 736–739
A non-fatal case of hantavirus cariopulmonary syndrome imported into the UK (ex Panama), July 2014 Atkinson B, Jameson LJ, Bovill BA, Aarons EJ, Clwlow J, Lumley S, Latham J, Jenkins MH, MacGowan AP, Simpson AJ, Ahmed J, Brooks TJ, Hewson R.
J Clin Virol. 2015 Jun;67:52-5
Prevalence of antibiotic resistance in Escherichia coli isolated from urine samples routinely referred by general practitioners in a large urban center in south west England Chin TL, MacGowan AP, Bowker KE, Elder F, Beck CR, McNulty C
J Antimicrob Chemother. 2015Jul;70(7):2167-9
The global threat of antimicrobial resistance: science for intervention. Roca I, Akova M, Baquero F, Carlet J, Cavaleri M, Coenen S, Cohen J, Findlay D, Gyssens I, Heuer OE, Kahlmeter G, Kruse H, Laxminarayan R, Liébana E, López-Cerero L, MacGowan A, Martins M, Rodríguez-Baño J, Rolain JM, Segovia C, Sigauque B, Tacconelli E, Wellington E, Vila J. New Microbes New Infect. 2015 Apr 16;6:22-9.
The role of microbial biofilms in prosthetic joint infections. JC. Acta Orthop. 2015 Apr;86(2):147-58
Gbejuade HO, Lovering AM, Webb.
Clinical presentation and microbiological diagnosis in paediatric respiratory tract infection: a systematic review. Thornton HV, Blair PS, Lovering AM, Muir P, Hay AD. Br J Gen Pract. 2015 Feb;65(631).
Colistin susceptibility testing: time for a review Albur M, Noel A, Bowker K, Macgowan A
J Antimicrob chemother. 2014 May;69(5):1432-4
Lack of upward creep of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the Uk and Ireland 2001-07 – authors response Reynolds R, Hope R, Warner M, MacGowan AP, Livermore DM, Ellington MJ; BSAC Extended Working Party on Resistance Surveillance
J Antimicrob Chemother. 2013 Jul;68(7):1693-4
Frontline antibiotic therapy MacGowan A, Albur M
Clin Med (Lond).2013 Jun;13(3):263-8
EUCAST expert rules in antimicrobial susceptibility testing Leclercq R, Canton R, Brown DF, Giske CG, Heisig P, MacGowan AP, Mouton JW, Nordmann P, Rodloff AC, Rossolini GM, Soussy CJ, Steinbakk M, Winstanley TG, Kahlmeter G
Clin Microbiol Infect. 2013 Feb;19(2):141-60
Activity of oritavancin against methicillin-resistnat staphylococci, vancomycin-resistant enterococci and ß-haemolytic streptococci collected from western European countries in 2011 Morrissey I, Seifert H, Canton R, Nordmann P, Stefani S, Macgowan A, Janes R, Knight D, Oritavancin Study Group
J Antimicrob Chemother. 2013 Jan;68(1):164-7
Lake of upward creap of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the UK and Ireland 2001-07 Reynolds R, Hope R, Warner M, MacGowan AP, Livermore DM, Ellington MJ; BSAC Extended Working Party on Resistance Surveillance
J Antimicrob Chemother. 2012 Dec;67(12):2912-8
Factors influencing the clinical outcome of methicillin-resistant Staphylococcus aureus bacteraemia Alubur MS, Bowker K, Weir I, MacGowan A.
Eur J Clin Microbiol Infect Dis. 2012 Mar:31(3):295-301
Does laboratory antibiotic susceptibility reporting influence primary care prescribing in urinary tract infection and other infections? McNulty CA, Lasseter GM, Charlett A, Lovering A, Howell-Jones R, MacGowan A, Thomas M
J Antimicrob chemother. 2011 Jun;66(6):1396-404
Use of intravenous co-trimoxazole to treat bacterial infection: analysis of 50 treatment episodes Barton E, MacGowan AP
J Chemother. 2010 Aug;22(4)67-9
Bacterial susceptibility to topical antimicrobials and clinical outcomes in bacterial keratits Kaye SB, Tuft S, Neal T, Tole D, Leeming JP, Figueiredo F, Armstrong M, Mcdonnell P, Tullo A ,Parry C
Invest Opthalmol & Visual Science 2010 51:362-8
Harmonization of antimicrobial susceptibility testing breakpoints in Europe: implications for reporting intermediate susceptibility Brown D, MacGowan A
J Antimicrob Chemother. 2010 Feb;65(2):183-5
Future treatment options for Grem-positive infections-looking ahead Barton E, MacGowan A
Clin Microbiol Infect. 2009 Dec;15 Supple 6:17-25
Mycobacteria and allograft heart valve banking: an international survey WarwickRM, Magee JG, Leeming JP, Graham JC, Hannan MM, Chadwick M, Crook DW, Yearsley CP, Reyer A, Parker R
J Hosp Infect. 2009 68:255-61
Headwear in laminar flow operating theatres. Gordon RJ, Bannister GC, Bowker KE et al.
J Hosp Infect. 2009 Nov;73(3):289-91
Storage of equipment above areas used for opening sterile theatre gowns: is there an infection risk? Pentlow A, Murray J, Bowker K.
J Hosp Infect. 2009 Oct;73(2):178-9.
Problems of basing patient recruitment for primary care studies on routine laboratory submissions. C.A.M.McNulty, M.Thomas, R.John, A.M.Lovering, D.Lewis, A.P.MacGowan
J Clin Pathol. 2007 Nov: 60(11) 1290-3
Clinical implications of antimicrobial resistance to therapy MacGowan AP; BSAC Working Party on Resistance Surveillance.
J Antimicrob Chemother. 2008 Nov;62 Suppl 2:ii105-14. Review.
Theatre shoes – a link in the common pathway of postoperative wound infection Amirfeyz R, Tasker A, Ali S, Bowker K, Blom A.
Ann R Coll Surg Engl. 2007 Sep;89(6):605-8.
Occurrence and current frequency of CTX-M-type beta-lactamases from a regional hospital in the South West of England. F.Tarrant, A.P.Macgowan, T.R.Walsh
J Antimicrob Chemother. 2007; Apr: 59, 815-6.
The effect of surgical approach to blood flow to the femoral head during resurfacing Khan A, Yates P, Lovering AM, Bannister GC, Spencer RF
J Bone & Joint Surgery. 2007; Jan: 89:21-5
Occurrence and current frequency of CTX-M type beta-lactamases from a regional hospital in the south-west of England Tarrant F, MacGowan AP, Walsh TR
J Antimicrob Chemother. 2007 Apr;59(4): 815-6
A multi-center study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides Wootton M, MacGowan, Walsh TR, Howe RA
J Clin Microbiol. 2007;Feb:45(2):329-32
European Committee on Antimicrobial Susceptibility testing (EUCAST) technical notes on antimicrobial susceptibility testing Clin Microbiol Infect. 2006 Jun; 12(6):501-3
Topical ethyl chloride fine spray. Does it have any antimicrobial activity? Burney K, Bowker K, Reynolds R, Bradley M.
Clin Radiol. 2006 Dec;61(12):1055-7.
Cavitatory lung disease complicating empyema in children Ramphul N, Eastham KM, Freeman R, Eltringham G, Kearns A, Leeming JP, Hasan A, Hamilton LJR , Spencer DA
Ped Pulmonology. 2006 41:750-53
Childhood empyema – limited potential impact of 7-valent pneumoccocal vconjugate vaccine Flether M, leemin JP, Cartwright K, Finn A
Paed Infect Dis Journal. 2006 25:559-60
Should finger rings be removed prior to scrubbing for theatre Kelsall NK, Griggs RK, Bowker KE, Bannister GC.
J Hosp Infect. 2006 Apr;62(4):450-2. Epub 2006 Feb 17.
Linezolid-induced inhibition of mitochondrial protein synthesis. A.S.De Vriese, R.V.Coster, J.Smet, S.Seneca, A.M.Lovering, L.L.Van Haute, L.J.Vanopdenbosch, J.J.Martin, C.C.Groote, S.Vandecasteele, J.R.Boelaert
Clin Infect Dis. 2006 Apr; 42, 1111-7
Expression of tcaA and mprF and glycopeptide resistance in clinical glycopeptide-intermediate Staphylococcus aureus (GISA) and heteroGISA strains Wootton M, MacGowan, Walsh TR
Biochem Biophys Acta. 2005 Nov 3;1726(3):326-7
Reduced expression of the atl autolysin gene and susceptibility to autolysis in clinical heterogenous glycopeptide-intermendiate Staphylococcus aureus (hVISA) and GISA strains Wootton M, Bennett PM, MacGowan, Walsh TR
J Antimicob Chemother. 2005 Nov;56(5): 944-7
Discrepancy between viable counts and light ouput as viability measurements, following ciprofloxacin challenge of self-bioluminescent Pseudomonas aeruginosa biofilms Marques CN, Salisbury VC, Greenman J, Bowker KE, Nelson SM.
J Antimicob Chemother. 2005 Oct;56(4): 665-71
Strain-specific expression levels of Pbp4 exist in isolates of glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA. M.Wootton, P.M.Bennett, A.P.MacGowan, T.R.Walsh
Antimicrob Agents Chemother. 2005 Aug; 49, 3598-9.
The relationship between primary care antibiotic prescribing and bacterial resistance in adults in the community: a controlled observational study using individual patient data. A.D.Hay, M.Thomas, A.Montgomery, M.Wetherell, A.M.Lovering, C.McNulty, D.Lewis, B.Carron, E.Henderson, A.P.MacGowan
J Antimicrob Chemother. 2005 Jul; 56, 146-53
Residual antibiotics in allograft heart valve tissue samples following antibiotic disinfection. J.L.Leeming, A.M.Lovering, C.J.Hunt
J Hosp Infect. 2005 Jul; 60, 231-4.
Topical fusidic acid/betamethasone-containing gel compared to systemic therapy in the treatment of canine acute moist dermatitis. Cobb MA, Edwards HJ, Jagger TD, Marshall J, Bowker KE.
Vet J. 2005 Mar;169(2):276-80.
Ventriculitis due to a hetero strain of vancomycin intermediate Staphylococcus aureus (hVISA): successful treatment with linezolid in combination with intraventricular vancomycin. F.Amod, I.Moodley, A.K.Peer, J.Sunderland, A.M.Lovering, M.Wootton, S.Nadvi, F.Vawda
J Infect. 2005 Apr; 50, 252-7.
Development of a novel assay method for colistin sulphomethate M.Wootton, H.A.Holt, A.P.MacGowan
Clin Microbiol Infect. 2005 Mar; 11, 243-4.
Diagnosis of invasive pneumococcal infection by serotype-specific urinary antigen detection Leeming JP, Cartwright K, MorrisR, Martin SA, Smith MD
Paed Infect Dis Journal. 2005 43:4972-6
Clincal features, aetiology and outcome of empyema in children in the northe east of england: a prospective hospital based study Eastman KM, Freeman R, Kearns A, Eltringham G, Clark J, Leeming JP, Spencer DA
Thorax. 2004 59:522-5
Genetic analysis of 17 genes in Staphylococcus aureus with reduced susceptibility to vancomycin (VISA) and hetero VISA. M.Wootton, M.B.Avison, P.M.Bennett, R.A.Howe, A.P.MacGowan, T.R.Walsh
J Antimicrob Chemother. 2004 Feb; 53, 406-7
Antimicrobial susceptibility of lower respiratory tract pathogens in Great Britain and Ireland 1999-2001 related to demographic and geographical factors: the BSAC Respiratory Resistance Surveillance Programme R.Reynolds, J.Shackcloth, D.Felmingham, A.P.MacGowan
J Antimicrob Chemother. 2003 Dec; 52, 931-43
Cefuroxime resistance in non-beta -lactamase Haemophilus influenzae is linked to ftsl Straker K, Wootton M, Simm AM, Bennett PM, MacGowanAP, Walsh TR
J Antimicob Chemother. 2003 Mar;51(3): 523-30
Culture-negative chilhood empyema is usually due to penicillin-sensitive Streptococcus pneumoniae capsular serotype 1 Eltringham G, Kearns A, Freeman R et al
J Clin Microbiol. 2003 41:521-522
Infection control of lung function equipment: a practical approach Kendrick AH, Johns DP, Leeming JP
Respiratory Medicine. 2003 97:1163-79
A novel polymerase chain reaction assay to detect Mycoplasma genitalium Eastick K, Leeming JP, Caul EO, Horenr PJ Millar MR
Molecular Pathology. 2003. 56:25-8
Bacterial contamination of surgical gloves by water droplets spilt after scrubbing. Heal JS, Blom AW, Titcomb D, Taylor A, Bowker K, Hardy JR.
J Hosp Infect. 2003 Feb;53(2):136-9.
Endemic heteroresistant glycopeptide intermediate Staphylococcus aureus (hGISA) comprising unrelated clonal types and not associated with vancomycin therapy. [French] E.Lecaillon, E.P.Gueudet, M.Wootton, T.R.Walsh, A.P.MacGowan, M.E.Jones
Pathologie et Biologie. 2002 Nov; 50, 525-9
Effect of jewellery on surface bacterial counts of operating theatres Bartlett GE, Pollard TC, Bowker KE, Bannister GC.
J Hosp Infect. 2002 Sep;52(1):68-70.
Bacterial strike-through of re-usable surgical drapes: the effect of different wetting agents Blom AW, Gozzard C, Heal J, Bowker K, Estela CM.
J Hosp Infect. 2002 Sep;52(1):52-5.
Direct measurement of bacterial penetration through surgical gowns: a new method Lankester BJ, Bartlett GE, Garneti N, Blom AW, Bowker KE, Bannister GC.
J Hosp Infect. 2002 Apr;50(4):281-5
Vancomycin therapeutic drug moitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UKNEQAS) for Antibiotic Asays questionnaire Tobin CM, Darville JM, Thomson AH, Sweeney G, Wilson JF, MacGowan AP, White LO
J Antimicrob Chemother. 2002 Nov;50(5):713-8
Expression of the lux genes in a clinical isolate of Streptococcus pneumoniae using bioluminescence to monitor gemifloxacin activity. Beard SJ, Salisbury V, Lewis RJ, MacGowan AP
Antimicrob Agents Chemother. 2002 Feb; 46, 538-42.
To disinfect or not to dsinfect the foot in total joint arthroplasty of the lower limb Blom AW, Lankaster B, Bowker KE, Bannis GC.
J Hosp Infect. 2001 Dec;49(4):304-5.
The passage of bacteria through surgical drapes Blom A, Estela C, Bowker K, MacGowan A, Hardy JR.
Ann R Coll Surg Engl. 2000 Nov;82(6):405-7.
Carriage of antibiotic-resistant bacteria by healthy children Millar M, Walsh TR, Freeman R et al
J Antimicrob Chemother. 2001 ;47:605-10
Evaluation of current methods of detection of staphylococci with reduced susceptibility to glycopeptides. Walsh TR, Bolstrom, A, Qwarnstrom A, Ho P, Wootton M, Howe RA, MacGowan AP, Diekema D
J Clin Microbiol 2001 Jul; 39: 2439-44.
A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother. 2001 Apr;47; 399-403.
Detection of glycopeptide resistance in Staphylococcus aureus. T.R.Walsh, R.A.Howe, M.Wootton, P.M.Bennett, A.P.MacGowan
J Antimicrob Chemother. 2001 Mar; 47: 357-8.
Investigation of an outbreak of ciprofloxacin-resistant Neisseria gonorrhoeae using a simplified opa-typing method Palmer HM, Leeming JP, Turner A.
Epidemiology and Infection. 2001.126:219-24
A multiplex polymerase chain reaction to differentiate B lactamse plasmids of Neisseria gonorrhoeae Palmer HM, Leeming JP, Turner A.
J Antimicrob Chemother. 2000. 45: 777-82
Diagnosis of invasive aspergillosis in bone marrow transplant recipients by polymerase chain reaction Williamson ECM, Leeming JP, Palmer HM et al
British Journal of Haematology. 2000; 108:132-9
Use of meropenem 3g once daily for outpatient treatment of infective exacerbations of bronchiectasis Darley ES, Bowker KE, Lovering AM, Harvey JE, Macgowan AP.
J Antimicrob Chemother. 2000 Feb;45(2):247-50.
Detection of extended-spectrum beta-lactamases with Etest and double-disc potentiation methods. D.F.Brown, J.Andrews, A.King, A.P.MacGowan AP
J Antimicrobl Chemother. 2000 Aug; 46: 327-8.
Heterogeneous resistance to vancomycin in Staphylococcus aureus. R.A.Howe, M.Wootton, T.R.Walsh, P.M.Bennett, A.P.MacGowan
J Antimicrob Chemother. 2000 Jan; 45: 130-2

 

Bcare (ARL) Contact Details

Antimicrobial Reference Laboratory
Level 2, Phase 1, Pathology Sciences Building
Southmead Hospital
Westbury-on-Trym
Bristol
BS10 5NB

Telephone: 0117 4146269 or 0117 4146220

Fax: 0117 4146282

Email: arlenquiries@nbt.nhs.uk

Bcare Research Articles

Bcare Grants

Regular Off Off

Funding Body

Project Title

Date Awarded

Role in Grant

Co-applicants

North Bristol NHS Trust

Flexibility and sustainability funding for NIHR pump priming activities

01/01/2008

Principal Investigator

AP MacGowan, AM Lovering

Western CLRN

Infrastructure funding

01/01/2008

Principal Investigator

AP MacGowan, AM Lovering

Western CLRN

Key support for funding equipment

01/01/2008

Principal Investigator

AM Lovering, KE Bowker

NIHR

Programme Grant: Blood stream infection: focus on outcomes

09/10/2008

Principal Investigator

AP MacGowan

NIHR-HTA

HTA: The diagnosis of urinary tract infection in young children (DUTY) study

01/01/2009

Co-applicant

AP MacGowan
EU/European CDC Development of a European susceptibility testing method 01/01/2008 Co-applicant AP MacGowan
North Bristol NHS Trust Flexibility and sustainability funding for NIHR pump priming activities 01/01/2009 Principal Investigator AP MacGowan, AM Lovering
NISCHR Research group: Microbiology and Infection Translational Research Group 01/01/2010 Co-applicant AP MacGowan, AM Lovering
Cerexa Pharmacodynamic assessment of the combination of ceftaroline plus NXL 104 against wild type and multi-resistant Enterobacteriacaea studied in an in vitro pharmacokinetic infection model 01/01/2009 Principal Investigator AP MacGowan, KE Bowker
Protez Pharmaceuticals Inc Pharmacodynamic assessment of PZ601 against Staphylococcus aureus and Enterobacteriacae: antibacterial effects of simulated human doses and assessment of T>MIC relationships 01/02/2008 Principal Investigator AP MacGowan, KE Bowker
Bayer Schering Healthcare Studies on sequential fluoroquinolone dosing in an in vitro pharmacokinetic model of infection: impact on antibacterial effect and risk of emergence of resistance 01/04/2007 Principal Investigator AP MacGowan, KE Bowker
Astellas Pharma Europe Ltd Comparative pharmacodynamics of telavancin, daptomycin, linezolid, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection 01/08/2007 Principal Investigator AP MacGowan, KE Bowker
Johnson & Johnson Pharmacodynamic assessment of doripenem and imipenem against Pseudomonas aeruginosa and Acinetobacter species: impact of T>MIC 01/07/2007 Principal Investigator AP MacGowan, KE Bowker
Basilea Pharmaceutica In vitro study to investigate the potency of new dihydrofolate reductase inhibitors against clinical Gram positive pathogens 01/05/2007 Principal Investigator AP MacGowan, KE Bowker
Mayne Pharma plc A Phase 1 randomised double blind cross over study to compare the pharmacokinetic/pharmacodynamic and safety characteristics of targocid with Mayne teicoplanin administered as single iv doses in healthy volunteers 01/07/2006 Principal Investigator AP MacGowan, AM Lovering
Hoffman La Roche The pharmacodynamics of the antibacterial effect and emergence of resistance to R04906463/CS-023/tomopenem in an in vitro pharmacokinetic model of S.aureus infection 01/05/2005 Principal Investigator AP MacGowan, KE Bowker
Basilea Pharmaceutica The in vitro potency of a novel Blactam/Blactamase inhibitor combination against P.aeruginosa, Enterobacter cloacae, Klebsiella Pneumoniae and E.coli using an in vitro pharmacokinetic model 01/07/2006 Principal Investigator AP MacGowan, KE Bowker
Basilea Pharmaceutica In vitro study to investigate the potency of BAL 30072 against clinical strains of Enterobacter species and Gram negative rods with defined resistance mechanisms 01/10/2006 Principal Investigator AP MacGowan, KE Bowker
Cubist Pharmaceuticals Determination of daptomycin and vancomycin MIC, MBC and kill curves on US MRSA isolates 01/08/2006 Co-Principal Investigator AP MacGowan, TR Walsh
Merck Sharp & Dohme The antibacterial effects of ceftriaxone, ertapenem and piperacillin-tazobactam against extended spectrum Blactamase strains of Enterobacteriacae in an in vitro pharmacokinetic model 01/01/2005 Principal Investigator AP MacGOwan, AR Noel, KE Bowker
GR Micro Ltd Comparative pharmacodynamics of daptomycin, vancomycin and teicoplanin in an in vitro pharmacokinetic model of infection 01/02/2005 Principal Investigator AP MacGowan, KE Bowker, AR Noel
European Union DGSANCO/European CDC Antibiotic susceptibility proposal 790806 01/01/2005 Co-applicant AP MacGowan
Department of Health Sentinel and population surveillance of Panton-Valentine leucocidin-positive S.aureus and community acquired MRA 01/06/2007 Co-Principal Investigator AM Lovering, AP MacGowan
National School for Primary Care Research, Department of Health Primary Care antibiotic prescribing and antimicrobial resistance (PCAAR) 01/02/2007 Co-Principal Investigator AM Lovering, AP MacGowan
Showering Fund An investigation of the reservoir of antibiotic resistance genes by the commercial bacteria of healthy community volunteers and how this impacts on the prevalence of antibiotic resistance in bacteria associated with UTI 01/07/2008 Principal Investigator AM Lovering
North Bristol NHS Trust Research Foundation Determination of protein binding of vancomycin in a general hospital patient population 01/06/2007 Principal Investigator AM Lovering
North Bristol NHS Trust Research Foundation An evaluation of the Bronkotest system for identification of respiratory infection 01/06/2007 Principal Investigator AM Lovering
Basilea The in vitro activity of BAL 30072 using simulated human serum pharmacokinetics against multiresistant Pseudomonas aeruginosa 01/01/2009 Co-Principal Investigator KE Bowker

 

Bcare Grants

pK/pD, MIC, MBC and Resistance Assays on Novel Antimicrobials

Regular Off Off

Assay Development

BCARE personnel have considerable in depth knowledge in the development of new high pressure liquid chromatography (HPLC) and LC/MS assays for antibacterials, antivirals and antifungals. Immunoassay technologies have also been extensively trialled prior to introduction into clinical practice. In recent times the BCARE staff have developed HPLC assays for anti viral and anti fungal agents and we are keen to pursue pharmacokinetic studies on antivirals. Our expertise in HPLC assay has also lead to an active research interest in antimicrobial metabolites and/or breakdown products.

Pharmacokinetics

The staff within BCARE have a considerable expertise in antimicrobial pharmacokinetics both in patients and healthy volunteers. In the recent past pharmacokinetic studies have been performed in ITU patients, patients with severe sepsis (bacteraemia, pulmonary infection, after surgery) and orthopaedics.

These pharmacokinetic interests overlap with our knowledge of antimicrobial assay development and pharmacodynamics. In addition to performing pharmacokinetic studies BCARE supports pharmacokinetic research in other centers by the provision of assay services and external quality assurance.

Pharmacodynamics

Pharmacodynamics is an expanding and well established area, and it complements our strong track record in the basic laboratory aspects of antimicrobial chemotherapy and pharmacokinetic evaluations. All pharmacodynamic activities are laboratory based; animals are not used. Expertise exists to perform simple investigations such as post-antibiotic effect through to complex antimicrobial dose fractionation studies using continuous bacterial culture in-vitro models. These models enable intravenous, intramuscular and oral drug concentration serum profiles to be modelled. Hollow fibre in-vitro pharmacokinetic models are also used in preclinical antibacterial drug evaluation. At present we have experience with β-lactams, quinolones, glycopeptides, aminoglycoside and other antimicrobials classes in our in-vitro model systems.

Many major pathogen groups can be studied using these systems, for example, staphylococci, streptococci, enterobacteriacae, haemophilus, pseudomonas and anaerobes.

Antimicrobial Susceptibility Testing Techniques

Expertise exists to perform susceptibility tests by agar dilution and micro-and macro-broth dilution techniques, and E strips. BSAC, EUCAST or CLSI methodologies are used. In addition, β-lactamase induction tests can be performed. Confirmation of hGISA/GISAs by population analysis profiles (PAPs) are available.

Bactericidal-time kill curves can be performed and bacterial killing with single agents and combinations studied, using novel, computer generated curve fitting techniques.

Current work:

  • in vitro susceptibility testing.
  • determination of minimum inhibitory concentrations (MICs).
  • bactericidal studies on antimicrobials.
  • antibacterial – antibacterial interactions.

Bcare (ARL) Contact Details

Antimicrobial Reference Laboratory
Level 2, Phase 1, Pathology Sciences Building
Southmead Hospital
Westbury-on-Trym
Bristol
BS10 5NB

Telephone: 0117 4146269 or 0117 4146220

Fax: 0117 4146282

Email: arlenquiries@nbt.nhs.uk

pK/pD, MIC, MBC and Resistance Assays on Novel Antimicrobials

Access to Culture Collection

Regular Off Off

Within the Department of Medical Microbiology at Southmead is a collection of >40,000 bacterial strains, mostly isolated from clinical specimens, about 3000 of which were isolated from blood cultures. The collection contains significant numbers of all the following species:

Gram positive aerobic cocci:

Enterococcus faecalis, Enterococcus faecium; Staphylococcus aureus, penicillinase negative, penicillinase positive, methicillin resistant; coagulase negative staphylococci (various species); Staphylococcus saprophyticus; Streptococci of Lancefield Groups A, B, C, F and G; penicillin-susceptible and penicillin resistant Streptococcus pneumoniae; viridans streptococci.

Gram positive aerobic bacilli: Bacillus spp:

Corynebacteria spp; Listeria monocytogenes; other Listeria spp.

Gram negative aerobic cocci:

Moraxella catarrhalis; Neisseria meningitidis; Neisseria gonorrhoeae.

Gram negative aerobic bacilli:

Haemophilus influenzae, β-lactamase-negative and β-lactamase-positive; Citrobacter spp; Enterobacter spp; Escherichia coli; (ESBL producers and others); Klebsiella spp; Morganella morgani; Proteus spp; Providencia spp; Salmonella typhi, other Salmonella spp; Serratia spp; Shigella spp; Hafnia alvei; Aeromonas spp; Acinetobacter spp; Campylobacter spp; Pseudomonas aeruginosa (with multiple resistance mechanisms) other Pseudomonas spp; Stentotrophomonas maltophilia.

Anaerobes: Actinomyces spp:

Bacteroides fragilis, other Bacteroides spp; Bifidobacterium spp; Clostridium difficile, Clostridium perfringens, other Clostridium spp; Eubacterium spp; Fusobacterium spp; Lactobacillis spp; Peptostreptococcus spp; Prevotella spp; Propionibacterium spp; Porphromonas spp; Veilonella spp.

Bcare (ARL) Contact Details

Antimicrobial Reference Laboratory
Level 2, Phase 1, Pathology Sciences Building
Southmead Hospital
Westbury-on-Trym
Bristol
BS10 5NB

Telephone: 0117 4146269 or 0117 4146220

Fax: 0117 4146282

Email: arlenquiries@nbt.nhs.uk

Access to Culture Collection

Bcare Services

Regular Off Off


BCARE has a record of research and development in the field of antimicrobial chemotherapy and resistance going back more than 35 years. These research activities inter-relate, support and augment several other activities such as running the UK National External Quality Assurance Scheme (UK NEQAS) for antibiotic assays and the provision of specialist antimicrobial assays for health providers in the UK.

Southmead and Frenchay Hospitals, situated in North Bristol, is the largest NHS trust in the South West of England with over 1000 beds and is a University of Bristol teaching trust which is one of two medical schools in the South West.

The Antimicrobial Reference Laboratory provides a comprehensive assay service for the purposes of therapeutic monitoring for a wide range of antimicrobial, antifungal and antiviral agents using both liquid chromatography and LC/MS methodology. This is the only such service provided in the UK and includes the provision of consultative advice on technical aspect of TDM and the clinical interpretation of assay results. The service has been provided since the mid 1980s and year-on-year there have been increases in both the number of laboratories using the service and the total number of samples assayed, with currently over 240 laboratories using the service each year. The full range of analytes assayed and some of the conditions under which they may need to be assayed are detailed in the assay book which is circulated annually.

The Antimicrobial Reference Laboratory also offers a comprehensive bacteriology service for both routine diagnostic and research purposes. These services include undertaking specialist susceptibility testing, such as minimum inhibitory and bactericidal concentrations, population analysis profiles for hVISA, serum cidal assays and bacterial kill curves. This is backed up with an expanding molecular diagnostics service which is able to undertake molecular detection of a range of pathogenicity and antimicrobial resistance genes, along with typing of organisms in epidemiological studies.

Bcare (ARL) Contact Details

Antimicrobial Reference Laboratory
Level 2, Phase 1, Pathology Sciences Building
Southmead Hospital
Westbury-on-Trym
Bristol
BS10 5NB

Telephone: 0117 4146269 or 0117 4146220

Fax: 0117 4146282

Email: arlenquiries@nbt.nhs.uk

Bcare Services
Subscribe to Regular